Back to Report Store Home

Frontier Pharma: Breast Cancer – First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

  • Published: Feb-2016
  • Report Code: GBIHC402MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 4

2.1 Exceptionally Large and Innovative Pipeline 4

2.2 Alignment of First-in-Class Molecular Target with Disease Causation 4

2.3 Highly Active Deals Landscape with Numerous Investment Opportunities 4

3 The Case for Innovation in the Breast Cancer Market 5

3.1 Growing Opportunities for Biologic Products 5

3.2 Diversification of Molecular Targets 5

3.3 Innovative First-in-Class Product Developments Remain Attractive 5

3.4 Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications 6

3.5 Sustained Innovation 6

3.6 Report Guidance 6

4 Clinical and Commercial Landscape 8

4.1 Disease Overview 8

4.2 Epidemiology 8

4.3 Disease Symptoms 9

4.4 Etiology 9

4.4.1 Age and Gender 9

4.4.2 Genetic Makeup 9

4.4.3 Environmental 10

4.5 Pathophysiology 10

4.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 10

4.5.2 Tumor Metabolic Shift 11

4.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 12

4.5.4 Cancer Stem Cells 13

4.6 Diagnosis 13

4.7 Prognosis and Disease Staging 14

4.7.1 Classification 15

4.8 Introduction to Breast Cancer Treatments 16

4.9 Surgery and Radiation Therapy 17

4.10 Overview of Marketed Products for Breast Cancer 17

4.10.1 Chemotherapy 18

4.10.2 Hormonal Therapies 19

4.10.3 Targeted Therapies 19

4.11 Treatment Algorithm 21

4.12 Current Unmet Need in Breast Cancer Market 23

5 Assessment of Pipeline Product Innovation 25

5.1 Breast Cancer Pipeline by Phase, Molecule Type and Molecular Target 25

5.2 First-in-Class Pipeline Programs 29

6 Signaling Network, Disease Causation and Innovation Alignment 36

6.1 The Complexity of Signaling Networks in Oncology 36

6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 37

6.3 First-in-Class Target Matrix Assessment 37

7 First-in-Class Target Evaluation 41**

7.1 Pipeline Programs which Target X 41

7.2 Pipeline Programs which Target X 42

7.3 Pipeline Programs which Target X 44

7.4 Pipeline Programs which Target X 44

7.5 Pipeline Programs which Target X 48

7.6 Conclusion 50

8 Deals and Strategic Consolidations 51

8.1 Industry-Wide First-in-Class Deals 51

8.2 Breast Cancer Deals Landscape 52

8.3 Licensing Deals 53

8.3.1 Molecule Type 55

8.3.2 Molecular Target 56

8.4 Co-development Deals 59

8.4.1 Molecule Type 60

8.4.2 Molecular Target 61

8.5 First-In-Class Molecules not Involved in Licensing or Co-development Deals 63

9 Appendix 67

9.1 Abbreviations 67

9.2 References 67

9.3 Contact Us 80

9.4 Disclaimer 80

**Note: ‘Target names in the Table of Contents have been removed until purchase’

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards